MARKET

NTEC

NTEC

Intec Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2600
-0.0079
-2.95%
After Hours: 0.2477 -0.0123 -4.73% 17:54 09/23 EDT
OPEN
0.2640
PREV CLOSE
0.2679
HIGH
0.2753
LOW
0.2430
VOLUME
1.95M
TURNOVER
--
52 WEEK HIGH
1.200
52 WEEK LOW
0.1324
MARKET CAP
18.01M
P/E (TTM)
-0.6318
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Intec Pharma to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
PR Newswire · 09/14 21:30
Intec Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference.
PR Newswire · 09/08 12:00
Intec Pharma prices registered direct offering
Through a registered direct offering, Intec Pharma (NASDAQ:NTEC) -9.2% AH, entered into a definitive agreement with Aspire Capital Fund for the purchase an
seekingalpha · 08/08 01:45
Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering
JERUSALEM, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund (“Aspire”) for the purchase and sale, in a registered direct offe
GlobeNewswire · 08/07 20:28
Intec Pharma EPS misses by $0.01
Intec Pharma (NASDAQ:NTEC): Q2 GAAP EPS of -$0.05 misses by $0.01. Cash and cash equivalents of $13.8M. Press Release
seekingalpha · 08/05 16:52
Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the second quarter ended June 30, 2020 and provides a corporate update.
PR Newswire · 08/05 11:00
Cannabis Stock Gainers And Losers From July 14, 2020
Gainers BIOHARVEST SCIENCES INC (OTC: CNVCF) shares closed up 29.55% at $0.10 Intec Pharma (NASDAQ: NTEC) shares closed up 13.83% at $0.30
Benzinga · 07/14 21:11
35 Stocks Moving in Monday's Pre-Market Session
Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares rose 88.2% to $2.39 in pre-market trading after declining over 5% on Thursday.
Benzinga · 07/06 11:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTEC. Analyze the recent business situations of Intec Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTEC stock price target is 0.3750 with a high estimate of 0.5000 and a low estimate of 0.2500.
EPS
Institutional Holdings
Institutions: 67
Institutional Holdings: 16.91M
% Owned: 24.42%
Shares Outstanding: 69.27M
TypeInstitutionsShares
Increased
10
1.51M
New
15
-295.82K
Decreased
3
48.35K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Director
John Kozarich
Chief Executive Officer/Vice Chairman/Director
Jeffrey Meckler
Chief Financial Officer
Nir Sassi
Chief Operating Officer
Nadav Navon
Chief Administrative Officer
Walt Linscott
Vice President
Liat Flaishon
Other
R. Michael Gendreau
Director
William Hayes
Director
Roger Pomerantz
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NTEC
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Intec Pharma Ltd stock information, including NASDAQ:NTEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTEC stock methods without spending real money on the virtual paper trading platform.